Head-to-head · free
Rapport Therapeutics vs Roche Holding AG
RAPP vs RHHBY — return on capital, cash generation, margins and balance sheet side by side.
RAPP
0 / 0
measures where RAPP leads
RHHBY
0 / 0
measures where RHHBY leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | RAPP · FY2025 | RHHBY |
|---|---|---|
| Revenue | — | — |
| Net income | (111.5M) | — |
| Revenue growth (yearly, multi-year) | — | — |
| Free cash flow | (88.1M) | — |
| Free cash flow margin | — | — |
| Net cash / (debt) | — | — |
| ROIC | — | — |
| Return on equity | -28.2% | — |
| Gross margin | — | — |
| Operating margin | — | — |
| Net debt / EBITDA | 0.42x | — |
Figures are as reported by each company; latest fiscal year shown.
Where Rapport Therapeutics's cash went (FY2025)
- Capital spending
- $616000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free